NCT01452334View on ClinicalTrials.gov

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Non-Hodgkin's LymphomaHodgkin LymphomaMultiple MyelomaChronic Myelogenous Leukemia
Interventions
BIOLOGICAL

BMS-936559 (Anti PD-L1)

Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY